FDA expands access to drug helping pancreatic cancer patients - AOL
AOL
Last updated: May 2, 2026
The Food and Drug Administration (FDA) has announced a new policy allowing certain pancreatic cancer patients to access a promising experimental drug, daraxonrasib, before its formal approval. This decision marks a significant step in accelerating treatment options for patients facing a difficult diagnosis.
- The FDA's action offers expanded access to daraxonrasib, a drug showing potential in treating specific forms of pancreatic cancer. This expedited access is typically granted under specific circumstances, often when a drug demonstrates significant promise and there are no satisfactory alternative treatments available. Pancreatic cancer remains a challenging disease with high mortality rates, making early access to innovative therapies crucial for affected patients. The policy aims to balance the need for rigorous drug approval processes with the urgency of providing potentially life-saving treatments to those in critical need. Further details regarding the specific criteria for patient eligibility and the drug's efficacy are expected to be released.
